David J. Waxman, PhD
Professor, Biology
Biography
David J. Waxman, PhD is a Biologist with extensive experience in the fields of biochemistry, molecular biology, and enzymology. Over the past 35 years, his lab has made seminal contributions to the research of cancer pharmacology and therapeutics, and steroid-metabolizing enzymes. His current interests include genomic and epigenetic mechanisms controlling liver gene expression, molecular endocrinology and cell signaling through transcriptional networks, role of angiogenesis and innate immune system in cancer therapy and pharmacology, and nuclear receptors and responses to environmental chemicals.
Dr. Waxman has spoken at over 130 conferences and has held appointments at a variety of universities including Harvard Medical School, MIT, and the Weizmann Institute.
Other Positions
- Member, Genome Science Institute, Boston University
- Professor, Gastroenterology, Medicine, Boston University Chobanian & Avedisian School of Medicine
- Member, Evans Center for Interdisciplinary Biomedical Research, Boston University
Education
- Harvard University, PhD
- Harvard University, AM
- Queens College, City University of New York, BA
Publications
- Published on 12/24/2024
Chang TY, Waxman DJ. HDI-STARR-seq: Condition-specific enhancer discovery in mouse liver in vivo. BMC Genomics. 2024 Dec 24; 25(1):1240. PMID: 39716078.
Read at: PubMed - Published on 9/25/2024
Kineman RD, Del Rio-Moreno M, Waxman DJ. Liver-specific actions of GH and IGF1 that protect against MASLD. Nat Rev Endocrinol. 2025 Feb; 21(2):105-117. PMID: 39322791.
Read at: PubMed - Published on 8/1/2024
Sonkar R, Ma H, Waxman DJ. Steatotic liver disease induced by TCPOBOP-activated hepatic constitutive androstane receptor: primary and secondary gene responses with links to disease progression. Toxicol Sci. 2024 Aug 01; 200(2):324-345. PMID: 38710495.
Read at: PubMed - Published on 6/26/2024
Chang TY, Waxman DJ. HDI-STARR-seq: Condition-specific enhancer discovery in mouse liver in vivo. Res Sq. 2024 Jun 26. PMID: 38978599.
Read at: PubMed - Published on 6/12/2024
Chang TY, Waxman DJ. HDI-STARR-seq: Condition-specific enhancer discovery in mouse liver in vivo. bioRxiv. 2024 Jun 12. PMID: 38915578.
Read at: PubMed - Published on 12/13/2023
Rampersaud A, Connerney J, Waxman DJ. Plasma growth hormone pulses induce male-biased pulsatile chromatin opening and epigenetic regulation in adult mouse liver. Elife. 2023 Dec 13; 12. PMID: 38091606.
Read at: PubMed - Published on 8/22/2023
Rampersaud A, Connerney J, Waxman DJ. Plasma Growth Hormone Pulsatility Directly Regulates Male-biased Chromatin Accessibility in Adult Mouse Liver. bioRxiv. 2023 Aug 22. PMID: 37662275.
Read at: PubMed - Published on 5/13/2023
Vázquez-Borrego MC, Del Río-Moreno M, Pyatkov M, Sarmento-Cabral A, Mahmood M, Pelke N, Wnek M, Cordoba-Chacon J, Waxman DJ, Puchowicz MA, McGuinness OP, Kineman RD. Direct and systemic actions of growth hormone receptor (GHR)-signaling on hepatic glycolysis, de novo lipogenesis and insulin sensitivity, associated with steatosis. Metabolism. 2023 Jul; 144:155589. PMID: 37182789.
Read at: PubMed - Published on 5/11/2023
Karri K, Waxman DJ. TCDD dysregulation of lncRNA expression, liver zonation and intercellular communication across the liver lobule. Toxicol Appl Pharmacol. 2023 Jul 15; 471:116550. PMID: 37172768.
Read at: PubMed - Published on 4/18/2023
Everton E, Del Rio-Moreno M, Villacorta-Martin C, Singh Bawa P, Lindstrom-Vautrin J, Muramatsu H, Rizvi F, Smith AR, Tam Y, Pardi N, Kineman R, Waxman DJ, Gouon-Evans V. Growth Hormone Accelerates Recovery From Acetaminophen-Induced Murine Liver Injury. bioRxiv. 2023 Apr 18. PMID: 37131727.
Read at: PubMed
View 352 more publications: View full profile at BUMC